A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)

Sponsor
Johnson & Johnson Private Limited
Study ID
NCT07141004
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Arthritis, Psoriatic

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Guselkumab — DRUG
    Guselkumab will be administered as subcutaneous injection.

Study Details

The purpose of this study is to evaluate the safety and how well guselkumab treatment works (efficacy) in participants with psoriatic arthritis (PsA; a chronic, autoimmune form of arthritis that causes joint inflammation) who had inadequate response to standard therapies.

Key Dates

Start date
Aug 12, 2025
Status verified
Jun 2026
Primary completion
Jun 5, 2027
Completion
Sep 11, 2027

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Guselkumab
    Participants will receive subcutaneous injections of guselkumab at Weeks 0, 4, 12, and 20.

Primary Outcome Measure

Number of Participants With Adverse Events (AEs) [ Time Frame: Up to 32 weeks ]

Central Contacts

Related Studies